Pegylated somatropin - Novo Nordisk

Drug Profile

Pegylated somatropin - Novo Nordisk

Alternative Names: NNC-126-0083; Pegylated recombinant human growth hormone - Novo Nordisk; Pegylated rhGH - Novo Nordisk

Latest Information Update: 03 Sep 2013

Price : $50

At a glance

  • Originator Novo Nordisk
  • Class Growth hormones; Hormonal replacements
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Somatotropin deficiency

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 05 Jul 2012 Discontinued - Phase-I for Somatotropin deficiency in Germany (SC)
  • 05 Jul 2012 Discontinued - Phase-II for Somatotropin deficiency in Belgium, Czech Republic, Denmark, France, Israel, Macedonia, Slovenia, Spain, Turkey and United Kingdom(SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top